BiovelocITA is now completing its second round of capital raising, making a total of 14.6 million euro to be used in developing highly innovative medical research projects. Banor SIM continues to support the Italian biotech accelerator and takes the contribution of primary private investors in BiovelocITA to 5.5 million euro.
Banknord has acquired an equity interest in the London-based company that manages Luxembourg’s BANOR SICAV (formerly Proxima Investments SICAV). Banknord has now changed its name to BANOR SIM Spa as part of its plan to achieve group status. The announcement was made by Massimiliano Cagliero, Chief Executive Officer and principal shareholder of BANOR SIM.